Athenex Inc (NASDAQ:ATNX) Director Jinn Wu bought 10,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were acquired at an average price of $13.64 per share, with a total value of $136,400.00. Following the transaction, the director now owns 249,208 shares of the company’s stock, valued at approximately $3,399,197.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Athenex Inc (NASDAQ ATNX) traded down $0.09 during trading on Friday, reaching $14.12. 353,645 shares of the company were exchanged, compared to its average volume of 372,366. Athenex Inc has a 52-week low of $11.21 and a 52-week high of $20.79. The stock has a market capitalization of $783.52 and a P/E ratio of -5.12.

Athenex (NASDAQ:ATNX) last released its earnings results on Thursday, November 9th. The company reported ($0.30) earnings per share (EPS) for the quarter. sell-side analysts anticipate that Athenex Inc will post -2.3 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC purchased a new stake in Athenex in the fourth quarter valued at approximately $161,000. California State Teachers Retirement System purchased a new stake in Athenex in the third quarter valued at approximately $198,000. Bank of New York Mellon Corp purchased a new stake in Athenex in the second quarter valued at approximately $240,000. Tudor Investment Corp ET AL purchased a new stake in Athenex in the second quarter valued at approximately $320,000. Finally, Virtus Fund Advisers LLC purchased a new stake in Athenex in the fourth quarter valued at approximately $333,000. Hedge funds and other institutional investors own 2.69% of the company’s stock.

A number of equities analysts have recently weighed in on ATNX shares. JPMorgan Chase & Co. boosted their price objective on shares of Athenex from $22.20 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, January 24th. BidaskClub raised shares of Athenex from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Finally, Deutsche Bank set a $20.00 price objective on shares of Athenex and gave the company a “buy” rating in a research report on Wednesday, January 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Athenex currently has a consensus rating of “Buy” and a consensus target price of $27.80.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/09/athenex-inc-atnx-director-acquires-136400-00-in-stock.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.